Laying to Rest Challenges in Managing Excessive Daytime Sleepiness in Patients with Obstructive Sleep Apnea or Narcolepsy – An Augmented Reality Experience

This activity is part of a series

Faculty

Richard K. Bogan, MD, FCCP, FAASM
Associate Clinical Professor
University of South Carolina Medical School, Columbia, SC
Medical University of South Carolina, Charleston, SC
Principal, Bogan Sleep Consultants, LLC
Columbia, SC
Richard K. Bogan, MD, FCCP, FAASM

Dr. Bogan is the President of Bogan Sleep Consultants, LLC. He is also Associate Clinical Professor at the University of South Carolina School of Medicine and Associate Clinical Professor at the Medical University of South Carolina in Charleston, S.C.

Dr. Bogan received his bachelor’s degree in chemistry from Wofford College and his MD degree from the Medical University of South Carolina in Charleston. He served his internship and residency, as well as Chief Medical Resident, at the University of Alabama Hospital and Clinics in Birmingham. Thereafter, he completed a fellowship and assistant professorship in the Pulmonary Division of the Department of Medicine at the University of Alabama School of Medicine. He has been certified by the American boards of Sleep Medicine, Internal Medicine and Pulmonary Diseases.

Dr. Bogan has served as principal investigator on numerous clinical trials in the past and continues to do so now. He has a variety of publications and research interests that focus on topics such as narcolepsy, insomnia, sleep apnea, shift work sleep disorder, restless legs syndrome/periodic limb movement disorder, chronic fatigue/fibromyalgia and circadian rhythm abnormality.

Michael J. Thorpy, MD
Professor of Neurology, Albert Einstein College of Medicine
Director, Sleep-Wake Disorders Center, Department of Neurology
Montefiore Medical Center, Bronx, NY
President, New York State Society of Sleep Medicine
Past President, Sleep Section of the Academy of Neurology
Michael J. Thorpy, MD

Dr. Thorpy is a Professor of Neurology at Albert Einstein College of Medicine and Director of the Sleep-Wake Disorders Center in the Department of Neurology at Montefiore Medical Center, both in New York. In addition to treating patients with sleep disorders, he conducts research in narcolepsy, insomnia and sleep apnea. He is President of the New York State Society of Sleep Medicine, Past President of the Sleep Section of the Academy of Neurology, and Past Secretary of the National Sleep Foundation. In 1993 Dr. Thorpy received the Nathaniel Kleitman Award from the American Academy of Sleep Medicine, one of the field’s highest honors, and in 2012 he received the Lifetime Achievement Award from the National Sleep Foundation.

Born in New Zealand, Dr. Thorpy earned his medical degree from the University of Otago Medical School. After receiving postgraduate training in Dunedin, New Zealand; Bombay, India; and London, England, he completed his residency in neurology at the State University of New York in Syracuse and a neuroendocrinology fellowship at Albert Einstein College of Medicine and Montefiore Medical Center. Dr. Thorpy is board certified in sleep medicine.

He has published extensively on narcolepsy, insomnia, and sleep disorders. He chaired the first International Classification of Sleep Disorders and has published more than 250 peer-reviewed articles and chapters, including publications in journals such as The New England Journal of Medicine. His numerous books include “The Encyclopedia of Sleep and Sleep Disorders“, ‘ ‘Parasomnias’ (2010), ‘Sleepiness” (2011), ‘Neuroimaging of Sleep and Sleep Disorders’ (2012), ‘Genetics of Sleep and Sleep Disorders’ (2013), ‘Narcolepsy: a clinical guide’ (2016),  and ‘SleepMultiMedia, a computerized textbook of sleep medicine’ (v12).0 (2023)

Dr. Thorpy has given more than 100 television, radio, and print interviews on sleep disorders.

Statement of Need

Excessive daytime sleepiness (EDS) is a common symptom of obstructive sleep apnea (OSA) and narcolepsy. EDS is often associated with traffic accidents and occupational incidents, cognitive impairments, and increased risk of medical and psychiatric comorbidities, resulting in poorer quality of life (QoL) and increased mortality. Yet, the burden of EDS is often underestimated and devising effective strategies for management poses a significant challenge.

Advances in sleep medicine have offered increasingly detailed insight into the physiology of the sleep-wake cycle and its associated neurotransmitters. Subsequently, recent clinical trials have revealed the efficacy and safety of novel therapies in improving outcomes in patients with OSA or narcolepsy experiencing EDS. Translating these data into evidence-based practices is critical to reduce the burden of EDS.

This virtual symposium will examine the impact of EDS on clinical outcomes, QoL, and psychosocial functioning as well as the subsequent need for early detection and effective treatment. In order to apply the latest scientific updates in sleep medicine, this symposium will feature Augmented Reality, enabling expert faculty to walk clinicians through the core physiological mechanisms involved in sleep and the means by which current and novel therapies exert their clinical impact. By navigating recent clinical trial data on these therapies, clinicians should be better able to apply the latest evidence to practice, optimizing the management of EDS in patients with narcolepsy or OSA.

Learning Objectives

At the end of this CME/CE activity, participants should be able to:

  • Recognize the burden of Excessive Daytime Sleepiness (EDS) in patients with Obstructive Sleep Apnea (OSA) or narcolepsy.
  • Apply the science of sleep to novel treatments for EDS to optimize treatment selection.
  • Integrate efficacy and safety data into treatment decisions for EDS in patients with OSA or narcolepsy to improve QoL and functioning.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Recognize the burden of EDS in patients with OSA or narcolepsy.
  • Explain the science of sleep for novel treatment decisions for EDS in patients with OSA or narcolepsy to improve QoL and functioning.
  • Recognize the burden of EDS in patients with OSA or narcolepsy.

Financial Support

Supported by an educational grant from Jazz Pharmaceuticals, Inc.

Target Audience

Sleep specialists, pulmonologists, psychiatrists, neurologists, primary care physicians, PAs, nurse practitioners, nurses, and pharmacists

Credit Information

Physicians (ACCME) 1.0 - Enduring

CME Outfitters, LLC, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nurses (ANCC) 1.0

This activity is designated for 1.0 contact hour.

PAs (AAPA) 1.0

CME Outfitters, LLC, has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credits. Approval is valid until the expiration date listed above. PAs should only claim credit commensurate with the extent of their participation.

Pharmacists/Pharmacy Tech (ACPE) 1.0

This application-based activity is approved for 1.0 contact hour (0.10 CEUs) of continuing pharmacy credit.

ABIM MOC - 1.0

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC point in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Royal College MOC

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

MIPS Improvement Activity

This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations. [Hard return + divider]


Dr. Bogan reports that he is a consultant for Harmony Biosciences, LLC; and Jazz Pharmaceuticals, Inc. He participates in industry funded research with Avadel/Flamel Ireland LTD; Axsome Therapeutics, Inc.; Balance; Elsai Inc.; Fresca; Jazz Pharmaceuticals Inc.; and Merck & Co., Inc. He is on the speakers bureau for Jazz Pharmaceuticals, Inc.; and Merck & Co., Inc. He is a shareholder, member of the Board of Directors, and Chief Medical Officer and employee of SleepMed, Inc. He receives other financial or material support as a member of the Board of Directors, First Community Corporation, SC and National Sleep Foundation.


Dr. Thorpy reports he receives research support from Avadel Pharmaceuticals; Axsome Therapeutics, Inc.; Balance Therapeutics; Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc. He is a consultant for Avadel Pharmaceuticals; Axsome Therapeutics, Inc.; Balance Therapeutics; Eisai Inc.; Harmony Biosciences, LLC; Jazz Pharmaceuticals, Inc. and Takeda Pharmaceuticals U.S.A., Inc.


  • Tony Graham, MD (peer reviewer) has no disclosures to report.
  • Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
  • Kashemi D. Rorie, PhD (planning committee) has no disclosures to report.
  • Evan Luberger (planning committee) has no disclosures to report.
  • Jan Perez (planning committee) has no disclosures to report.
  • Sharon Tordoff (planning committee) has no disclosures to report.
  • Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Additional Formats

Post-tests, credit request forms, and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit our Privacy & Confidentiality page.

Questions about this activity?

Call us at 877.CME.PROS (877.263.7767).

 


NOTE: Pharmacist CE Universal Activity Number, Enduring: 0376-0000-20-010-H01-P.

 

MMV-098-061620-43

Laying to Rest Challenges in Managing Excessive Daytime Sleepiness in Patients with Obstructive Sleep Apnea or Narcolepsy – An Augmented Reality Experience
Event Date: 06/16/2020